Cargando…

Vasopressin V(1B) Receptor Antagonists as Potential Antidepressants

Accumulating evidence shows that certain populations of depressed patients have impaired hypothalamus-pituitary-adrenal (HPA) axis function. Arginine-vasopressin (AVP) is one of the primary factors in HPA axis regulation under stress situations, and AVP and its receptor subtype (V(1B) receptor) play...

Descripción completa

Detalles Bibliográficos
Autor principal:	Chaki, Shigeyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278797/ https://www.ncbi.nlm.nih.gov/pubmed/33733667 http://dx.doi.org/10.1093/ijnp/pyab013

Ejemplares similares

Role of Serotonergic System in the Antidepressant Actions of mGlu2/3 Receptor Antagonists: Similarity to Ketamine
por: Chaki, Shigeyuki, et al.
Publicado: (2019)

Vasopressin and Vasopressin Receptor Antagonists
por: Oh, Yun Kyu
Publicado: (2008)

Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants
por: Chaki, Shigeyuki, et al.
Publicado: (2015)

Targeting of Metabotropic Glutamate Receptors for the Development of Novel Antidepressants
por: Chaki, Shigeyuki, et al.
Publicado: (2019)

On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039
por: Pałucha-Poniewiera, Agnieszka, et al.
Publicado: (2010)

Vasopressin receptor antagonists and their role in clinical medicine
por: Narayen, Girish, et al.
Publicado: (2012)

The Role of Arginine-Vasopressin in Stroke and the Potential Use of Arginine-Vasopressin Type 1 Receptor Antagonists in Stroke Therapy: A Narrative Review
por: Chojnowski, Karol, et al.
Publicado: (2023)

Is Metabolism of (R)-Ketamine Essential for the Antidepressant Effects?
por: Chaki, Shigeyuki
Publicado: (2017)

Beyond Ketamine: New Approaches to the Development of Safer Antidepressants
por: Chaki, Shigeyuki
Publicado: (2017)

Hyponatremia: A role for vasopressin receptor antagonists?
por: Ramesh, Gourishankar
Publicado: (2018)

Vasopressin Receptor Antagonists in Hyponatremia: Uses and Misuses
por: Rondon-Berrios, Helbert, et al.
Publicado: (2017)

Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics
por: Manning, M, et al.
Publicado: (2012)

Hyponatremia Associated with Congestive Heart Failure: Involvement of Vasopressin and Efficacy of Vasopressin Receptor Antagonists
por: Ishikawa, San-e, et al.
Publicado: (2023)

Role of Oxytocin and Vasopressin in Neuropsychiatric Disorders: Therapeutic Potential of Agonists and Antagonists
por: Cid-Jofré, Valeska, et al.
Publicado: (2021)

Role of 5-HT(1A) Receptor Stimulation in the Medial Prefrontal Cortex in the Sustained Antidepressant Effects of Ketamine
por: Fukumoto, Kenichi, et al.
Publicado: (2017)

Rapid and Sustained Antidepressant Action of the mGlu2/3 Receptor Antagonist MGS0039 in the Social Defeat Stress Model: Comparison with Ketamine
por: Dong, Chao, et al.
Publicado: (2016)

Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V(2)-Receptor Antagonist Tolvaptan
por: Gaglio, Paul, et al.
Publicado: (2012)

Is the History Repeated? Can (2R,6R)-Hydroxynorketamine be Another Antidepressant?
por: Chaki, Shigeyuki, et al.
Publicado: (2018)

Therapeutic Potential of a Vasopressin V2 Receptor Antagonist for Calcium Channel Blocker-Associated Edema with Vasospastic Angina
por: Toda, Kojiro, et al.
Publicado: (2022)

Synthesis and Biological Evaluation of Substituted Desloratadines as Potent Arginine Vasopressin V2 Receptor Antagonists
por: Mu, Shuai, et al.
Publicado: (2014)

Development of a human vasopressin V(1a)-receptor antagonist from an evolutionary-related insect neuropeptide
por: Di Giglio, Maria Giulia, et al.
Publicado: (2017)

Metabotropic Glutamate Receptors: Potential Drug Targets for Psychiatric Disorders
por: Yasuhara, Akito, et al.
Publicado: (2010)

Vasopressin receptors V1(a) and V2 are not osmosensors
por: Lykke, Kasper, et al.
Publicado: (2015)

Targeting the Arginine Vasopressin V(1b) Receptor System and Stress Response in Depression and Other Neuropsychiatric Disorders
por: Kanes, Stephen J, et al.
Publicado: (2023)

The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington’s Disease
por: Maibach, Hilda T., et al.
Publicado: (2022)

Vasopressin Receptor Antagonists for the Correction of Hyponatremia in Chronic Heart Failure: An Underutilized Therapeutic Option in Current Clinical Practice?
por: De Vecchis, Renato, et al.
Publicado: (2016)

The 5-HT(1B) receptor - a potential target for antidepressant treatment
por: Tiger, Mikael, et al.
Publicado: (2018)

Antagonists of the Vasopressin V1 Receptor and of the β(1)-Adrenoceptor Inhibit Cytotoxic Brain Edema in Stroke by Effects on Astrocytes – but the Mechanisms Differ
por: Hertz, Leif, et al.
Publicado: (2014)

Vasopressin mediates fructose-induced metabolic syndrome by activating the V1b receptor
por: Andres-Hernando, Ana, et al.
Publicado: (2021)

Evaluation of the Safety, Tolerability, and Pharmacokinetic Profiles of TP0473292 (TS-161), A Prodrug of a Novel Orthosteric mGlu2/3 Receptor Antagonist TP0178894, in Healthy Subjects and Its Antidepressant-Like Effects in Rodents
por: Watanabe, Mai, et al.
Publicado: (2021)

Efficacy and Safety of Vasopressin Receptor Antagonists for Euvolemic or Hypervolemic Hyponatremia: A Meta-Analysis
por: Zhang, Xiangyun, et al.
Publicado: (2016)

Oxytocin and Vasopressin Involved in Restraint Water-Immersion Stress Mediated by Oxytocin Receptor and Vasopressin 1b Receptor in Rat Brain
por: Zhao, Dong-Qin, et al.
Publicado: (2011)

The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials
por: Yan, Long, et al.
Publicado: (2015)

Evidence for Effective Multiple K(+)-Current Inhibitions by Tolvaptan, a Non-peptide Antagonist of Vasopressin V(2) Receptor
por: Lu, Te-Ling, et al.
Publicado: (2019)

Temporal trends of a vasopressin V(2) receptor antagonist in heart failure using a nationwide database in Japan
por: Kuragaichi, Takashi, et al.
Publicado: (2020)

Neuroprotective Effect of Aurantio-Obtusin, a Putative Vasopressin V(1A) Receptor Antagonist, on Transient Forebrain Ischemia Mice Model
por: Paudel, Pradeep, et al.
Publicado: (2021)

MicroED structure of the human vasopressin 1B receptor
por: Shiriaeva, Anna, et al.
Publicado: (2023)

Cardiac output improvement by pecavaptan: a novel dual‐acting vasopressin V1a/V2 receptor antagonist in experimental heart failure
por: Mondritzki, Thomas, et al.
Publicado: (2020)

Exploring the Potential Antidepressant Mechanisms of TNFα Antagonists
por: Brymer, Kyle J., et al.
Publicado: (2019)

Untargeted Metabolomics Reveals the Potential Antidepressant Activity of a Novel Adenosine Receptor Antagonist
por: Smith, Arnold Petrus, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g9fu9l55j86ik5cuud64vpep1r